Dr. Santosh Kesari is currently the Director of the Neuro-Oncology Program, Director of the Neurotoxicity Treatment Center, and Director of the Translational Neuro-Oncology Laboratories at Moores Cancer Center and a Professor of Neurosciences at the UC San Diego School of Medicine. Prior to coming to UC San Diego in 2009, he was an Assistant Professor of Neurology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston from 2003 to 2009.

Dr. Kesari was determined to be among the top 1% neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd., which reports its findings as the U.S. News & World Report Top Doctor list.  He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 200 scientific publications and is the inventor on several patents and patent applications.

Dr. Kesari is board certified in Medical Oncology and Neurology. He completed his residency at Massachusetts General Hospital/Brigham and Women’s Hospital in Boston and his fellowship at the Dana-Farber Cancer Institute in Boston. He earned a Ph.D. degree in molecular biology and a medical degree from the University of Pennsylvania School of Medicine. He is a member of the Society of Neuro-Oncology, American Society of Clinical Oncology, Indian Society of Neuro-Oncology, and American Academy of Neurology.

Dr. Ivan Babic has over 15 years of experience in translational oncology, and has been actively involved in pre-clinical and clinical drug development. He has held positions at UCLA and UCSD, and was Principal Investigator with the John Wayne Cancer Institute where his lab focused on identifying small molecule therapeutics directly targeting tumor metabolism. Dr. Babic earned his Ph.D. degree in biochemistry from the University of Calgary and completed his post-doctoral fellowship at David Geffen School of Medicine at UCLA. He is a member of the American Association for Cancer Research and is author of over 30 scientific publications. He is founder of Gilman Biosciences, NERD BIO, and co-founder of MD2 Biosciences Inc., holds several patents for small molecule therapeutics, and is inventor of several novel drug-screening assays.